| Indicators | Browse All

Cartesian Therapeutics, Inc. (RNAC)

Healthcare | Biotechnology | Frederick, United States | NasdaqGM
8.63 USD -0.83 (-8.774%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★★☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 7 a.m. EDT

The long-term investment case is effectively zero due to a catastrophic multi-year decline. The stock has lost nearly 97% of its value over the last nine years, with four consecutive years of negative annual returns ending recently. This persistent downward trajectory, combined with negative revenue growth of roughly 93%, negative operating margins, and a negative book value, signals a deteriorating business rather than a temporary setback. The market has correctly priced in the lack of sustainable fundamentals. In the short term, the picture is equally bleak despite some recent price recovery. While the stock has bounced off its lows, the statistical forecast models predict a further decline of roughly 7.5% over the next 45 days, and options data confirms this bearish sentiment with heavy put positioning and minimal call interest. The recent price action appears to be a dead-cat bounce rather than a reversal of the structural decline. With no dividend to provide income and a balance sheet showing negative equity, there is no margin of safety here.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.159105
AutoETS0.159105
MSTL0.159138
AutoTheta0.159186

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 36%
H-stat 1.02
Ljung-Box p 0.000
Jarque-Bera p 0.156
Excess Kurtosis -1.30
Attribute Value
Sector Healthcare
Revenue per Share 0.068
Market Cap 253,562,464
Forward P/E -3.22
Beta 0.46
Website https://www.cartesiantherapeutics.com

As of July 11, 2026, 7 a.m. EDT: Speculators are positioning for a significant downside move. Put open interest is heavily concentrated at the $5 strike, acting as a major floor, while call open interest is negligible. The volume-to-open-interest ratio for puts at the $7.5 strike indicates active selling pressure, whereas call activity is minimal. Implied volatility remains elevated, suggesting the market expects continued turbulence rather than a stable trend.


Info Dump

Attribute Value
52 Week Change -0.27565086
Address1 7,495 New Horizon Way
All Time High 840.0
All Time Low 5.6
Ask 10.62
Ask Size 2
Audit Risk 9
Average Daily Volume10 Day 252,210
Average Daily Volume3 Month 290,401
Average Volume 290,401
Average Volume10Days 252,210
Beta 0.459
Bid 6.5
Bid Size 2
Board Risk 9
Book Value -5.189
City Frederick
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 8.63
Current Ratio 7.654
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 9.19
Day Low 8.25
Display Name Cartesian Therapeutics
Earnings Timestamp 1,777,552,200
Earnings Timestamp End 1,777,552,200
Earnings Timestamp Start 1,777,552,200
Ebitda -88,897,000
Ebitda Margins 0.0
Enterprise To Ebitda -1.651
Enterprise To Revenue 82.691
Enterprise Value 146,776,464
Eps Current Year -3.35
Eps Forward -2.68
Eps Trailing Twelve Months -5.27
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 8.1263
Fifty Day Average Change 0.50370026
Fifty Day Average Change Percent 0.06198396
Fifty Two Week Change Percent -27.565086
Fifty Two Week High 14.56
Fifty Two Week High Change -5.9300003
Fifty Two Week High Change Percent -0.40728024
Fifty Two Week Low 5.6
Fifty Two Week Low Change 3.0300002
Fifty Two Week Low Change Percent 0.5410715
Fifty Two Week Range 5.6 - 14.56
Financial Currency USD
First Trade Date Milliseconds 1,466,602,200,000
Float Shares 10,630,819
Forward Eps -2.68
Forward P E -3.2201493
Free Cashflow -46,870,876
Full Exchange Name NasdaqGM
Full Time Employees 75
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,782,864,000
Gross Margins 0.0
Gross Profits -61,048,000
Has Pre Post Market Data 1
Held Percent Insiders 0.53683
Held Percent Institutions 0.25183
Implied Shares Outstanding 29,381,514
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 0
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,712,275,200
Last Split Factor 1:30
Long Business Summary Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Long Name Cartesian Therapeutics, Inc.
Market us_market
Market Cap 253,562,464
Market State PRE
Max Age 86,400
Message Board Id finmb_371375105
Most Recent Quarter 1,774,915,200
Net Income To Common -151,774,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 253,268,650
Number Of Analyst Opinions 7
Open 8.88
Operating Cashflow -72,968,000
Operating Margins -339.73077
Overall Risk 9
Payout Ratio 0.0
Phone 301 348 8698
Previous Close 9.46
Price Eps Current Year -2.5761194
Price Hint 2
Price To Book -1.6631335
Price To Sales Trailing12 Months 142.8521
Profit Margins 0.0
Quick Ratio 7.457
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.83
Regular Market Change Percent -8.77378
Regular Market Day High 9.19
Regular Market Day Low 8.25
Regular Market Day Range 8.25 - 9.19
Regular Market Open 8.88
Regular Market Previous Close 9.46
Regular Market Price 8.63
Regular Market Time 1,783,972,800
Regular Market Volume 259,932
Return On Assets -0.16364
Revenue Growth -0.929
Revenue Per Share 0.068
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 29,381,514
Shares Percent Shares Out 0.0642
Shares Short 1,886,695
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 2,291,824
Short Name Cartesian Therapeutics, Inc.
Short Percent Of Float 0.1451
Short Ratio 3.75
Source Interval 15
State MD
Symbol RNAC
Target High Price 44.0
Target Low Price 16.0
Target Mean Price 34.57143
Target Median Price 39.0
Total Cash 118,641,000
Total Cash Per Share 4.038
Total Debt 11,855,000
Total Revenue 1,775,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -5.27
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 7.70265
Two Hundred Day Average Change 0.92735004
Two Hundred Day Average Change Percent 0.120393634
Type Disp Equity
Volume 259,932
Website https://www.cartesiantherapeutics.com
Zip 21,703